Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.

Advances in experimental medicine and biology - 1 Jan 2016

Takai Erina, Totoki Yasushi, Nakamura Hiromi, Kato Mamoru, Shibata Tatsuhiro, Yachida Shinichi

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies. The genomic landscape of the PDAC genome features four frequently mutated genes (KRAS, CDKN2A, TP53, and SMAD4) and dozens of candidate driver genes altered at low frequency, including potential clinical targets. Circulating cell-free DNA (cfDNA) is a promising resource to detect molecular characteristics of tumors, supporting...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to High-Throughput Nucleotide Sequencing

Share to Molecular Diagnostic Techniques

Share to Pancreatic Neoplasms

Share to Precision Medicine

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 27753011
DOI: 10.1007/978-3-319-42044-8_3

Genes

KRAS
SMAD4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.PMID 27753011Read ↗

Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer.Semantic proximity Read ↗

Prognostic Implications of Multiplex Detection of KRAS Mutations in Cell-Free DNA from Patients with Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Circulating tumor DNA: toward evolving the clinical paradigm of pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Somatic Mutation Detection in Tumor Tissue and Matched Cell-Free DNA Using PCR-Based Methods in Pancreatic Cancer Patients Undergoing Upfront ResectionSemantic proximity Read ↗

Detection of mutated KRAS, TP53, CDKN2A, and SMAD4 in tumor cell-free DNA of Brazilian pancreatic adenocarcinoma patients using next-generation sequencing.Semantic proximity Read ↗

Detection of mutated KRAS, TP53, CDK2A, and SMAD4 in tumor cell-free DNA of Brazilian pancreatic adenocarcinoma patients using next-generation sequencingSemantic proximity Read ↗

Digital PCR-based plasma cell-free DNA mutation analysis for early-stage pancreatic tumor diagnosis and surveillance.Semantic proximity Read ↗

High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients.Semantic proximity Read ↗

Targeted Transcriptome and KRAS Mutation Analysis Improve the Diagnostic Performance of EUS-FNA Biopsies in Pancreatic Cancer.Semantic proximity Read ↗

Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer.Semantic proximity Read ↗

Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.